A High Court judgment on a judicial review brought by the British Generic Manufacturers Association (BGMA) has dismissed the organisation’s claim that it was unfairly excluded from talks on the next Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).
The UK’s BioIndustry Association (BIA) and Clarivate have published their latest report into biotech financing for the period December 2022 to February 2023.
What is the future for UK-based biotechnology? This article reviews the financing of, and governmental support for, the sector and considers the potential impact of new technology in the development of the life sciences.
New research has found that the public believes a new approach should be adopted for making funding decisions about treatments for rare diseases. The report ‘Rare insights: examining the social values of treating rare diseases’, was commissioned by the UK BioIndustry Association’s (BIA) Rare Disease Industry Group (RDIG).
The UK BioIndustry Association (BIA) appears to have won a reprieve on proposed cuts to SME R&D tax credits, via a letter from Chancellor Jeremy Hunt. The policy was introduced in the Government’s Autumn Statement in November 2022, due to take effect in April 2023.
